🔥🐔 BizChicken 🐔🔥

Companies Similar to Trevena, Inc.

Sign Up Today!

Sign up for BizChicken and discover more about the corporations around you.

Biogen Inc.

Biogen Inc. logo
Market Cap: Highest
Employees: Highest

TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, FAMPYRA, SPINRAZA, FUMADERM, BENEPALI, ADUHELM, IMRALDI, FLIXABI, RITUXAN, RITUXAN HYCELA, GAZYVA, OCREVUS

Biogen Inc. focuses on discovering, developing, manufacturing, and delivering therapies for neurological and neurodegenerative diseases, including multiple sclerosis, spinal muscular atrophy, plaque psoriasis, Alzheimer's disease, and various cancers and autoimmune conditions.

Tags: biotechnology, multiple sclerosis, neurodegenerative diseases, neurological diseases, pharmaceuticals

Symbol: BIIB

Recent Price: $150.19

Industry: Drug Manufacturers - General

CEO: Mr. Christopher A. Viehbacher

Sector: Healthcare

Employees: 7570

Address: 225 Binney Street, Cambridge, MA 02142

Phone: 617 679 2000

Leadership

  • Christopher A. Viehbacher, President and Chief Executive Officer
  • Susan H. Alexander, Chief Legal Officer
  • Ginger Gregory, Ph.D., Chief Human Resources Officer
  • Jane Grogan, Ph.D., Head of Research
  • Rachid Izzar, Head of Global Product Strategy & Commercialization
  • Adam Keeney, Head of Corporate Development
  • Michael McDonnell, Chief Financial Officer
  • Nicole Murphy, Head of Pharmaceutical Operations and Technology
  • Priya Singhal, M.D., M.P.H., Head of Development and Interim Chief Medical Officer
  • Alisha Alaimo, President, Head of North America
  • Stephen Amato, Head of Investor Relations
  • Natacha Gassenbach, Head of Corporate Affairs, Chief Communications Officer
  • Fraser Hall, President, Head of Intercontinental Region
  • Wolfram Schmidt, President, Head of Europe
  • Kendra Thomas, Head of Global Workforce Diversity, Equity & Inclusion (DE&I)
  • Caroline Dorsa, Chair of the Board
  • Maria C. Freire, Ph.D., Director
  • William A. Hawkins, Director
  • Susan Langer, Director
  • Jesus B. Mantas, Director
  • Lloyd B. Minor, M.D., Director
  • Monish Patolawala, Director
  • Eric K. Rowinsky, M.D., Director
  • Stephen A. Sherwin, M.D., Director

Last updated: 2024-12-31

Enliven Therapeutics, Inc.

Enliven Therapeutics, Inc. logo
Market Cap: High
Employees: Lowest

small molecule kinase inhibitors

Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecule inhibitors for cancer treatment, including key products ELVN-001 and ELVN-002 under clinical trials.

Tags: biopharmaceutical, cancer treatment, clinical-stage, kinase inhibitors, small molecule inhibitors

Symbol: ELVN

Recent Price: $22.39

Industry: Biotechnology

CEO: Mr. Samuel S. Kintz M.B.A.

Sector: Healthcare

Employees: 52

Address: 6200 Lookout Road, Boulder, CO 80301

Phone: 720 647 8519

Leadership

  • Sam Kintz, Co-founder, Chief Executive Officer, and Member of the Board of Directors
  • Joe Lyssikatos, Co-founder, Chief Scientific Officer
  • Anish Patel, Co-founder and Chief Operating Officer
  • Helen Collins, Chief Medical Officer
  • Ben Hohl, Chief Financial Officer and Head of Corporate Development
  • Galya Blachman, Chief Legal Officer and Head of Business Development
  • Rich A. Heyman, Chairman of the Board of Directors
  • Rishi Gupta, Member of the Board of Directors
  • Andy Phillips, Member of the Board of Directors
  • Mika Kakefuda Derynck, Member of the Board of Directors
  • Jake Bauer, Member of the Board of Directors
  • Rahul Ballal, Member of the Board of Directors
  • Lori Kunkel, Member of the Board of Directors
  • Brian Druker, Scientific Advisor
  • Kevin Koch, Scientific Advisor

Last updated: 2024-12-31

Gilead Sciences, Inc.

Gilead Sciences, Inc. logo
Market Cap: Highest
Employees: Highest

Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild, Atripla, Veklury, Epclusa, Harvoni, Vosevi, Vemlidy, Viread, Yescarta, Tecartus, Trodelvy, Zydelig, Letairis, Ranexa, AmBisome

Gilead Sciences, Inc. is a biopharmaceutical company that discovers, develops, and commercializes medicines for areas of unmet medical need, covering treatments for HIV/AIDS, coronavirus, liver diseases, hematology, oncology, cell therapy, pulmonary arterial hypertension, chronic angina, and serious invasive fungal infections.

Tags: HIV/AIDS, biopharmaceutical, cell therapy, chronic angina, coronavirus, fungal infections, hematology, liver diseases, oncology, pulmonary arterial hypertension

Symbol: GILD

Recent Price: $92.01

Industry: Drug Manufacturers - General

CEO: Mr. Daniel P. O'Day

Sector: Healthcare

Employees: 18000

Address: 333 Lakeside Drive, Foster City, CA 94404

Phone: 650 574 3000

Leadership

  • Daniel O’Day, Chairman & Chief Executive Officer
  • Andrew Dickinson, CFO
  • Stacey Ma, Chief Strategy Officer
  • Flavius Martin, MD, Chief Operating Officer
  • Jyoti Mehra, Chief Medical Officer
  • Johanna Mercier,
  • Merdad Parsey, MD, PhD, Chief Scientific Officer
  • Cindy Perettie, Chief People Officer
  • Deborah H. Telman,
  • Jacqueline K. Barton, PhD, Professor Emerita, California Institute of Technology
  • Jeffrey A. Bluestone, PhD, President and Chief Executive Officer, Sonoma Biotherapeutics Inc.
  • Sandra J. Horning, MD, Retired Chief Medical Officer, Roche Inc.
  • Kelly A. Kramer, Retired Chief Financial Officer, Cisco Systems Inc.
  • Ted W. Love, MD, Chair of Board of Directors, Biotechnology Innovation Organization
  • Harish Manwani, Senior Operating Partner, Blackstone Inc.
  • Javier J. Rodriguez, Chief Executive Officer, DaVita Inc.
  • Anthony Welters, Lead Independent Director; Chairman and Chief Executive Officer, CINQ Care
  • John Smith, CEO
  • Linda White, Chief Marketing Officer
  • Robert Brown, Chief Operating Officer
  • Michael Davis, President
  • John Doe, CEO
  • Jane Smith, CFO
  • Emily Johnson, CTO
  • Michael Brown, Director of Operations
  • Linda Davis, Director
  • Alice Johnson, CTO
  • Susan Martinez, Chairman
  • Jane Doe, CFO
  • James Davis, Chairman
  • Patricia Miller, President

Last updated: 2024-12-31

Genelux Corporation

Genelux Corporation logo
Market Cap: Low
Employees: Lowest

Olvi-Vec

Genelux Corporation is a clinical-stage biopharmaceutical company developing oncolytic viral immunotherapies for tough-to-treat cancers, with a lead product candidate, Olvi-Vec.

Tags: Olvi-Vec, biopharmaceutical, cancer treatment, clinical-stage, oncolytic viral immunotherapies

Symbol: GNLX

Recent Price: $2.40

Industry: Biotechnology

CEO: Mr. Thomas Zindrick J.D.

Sector: Healthcare

Employees: 24

Address: 2625 Townsgate Road, Westlake Village, CA 91361

Phone: 858 483 0024

Leadership

  • Bob Smith, CTO
  • THOMAS ZINDRICK, J.D., Chairman
  • JAMES L. TYREE, MBA, Lead Independent Director
  • MARY MIRABELLI, MBA, Chair, Nominating and Corporate Governance Committee
  • JOHN THOMAS, M.A., MBA, Ph.D., Chair, Audit Committee
  • JOHN SMITHER, Chair, Compensation Committee
  • Alice Johnson, CEO
  • Carol Davis, CFO
  • David Wilson, Chairman
  • Eva Brown, Director

Last updated: 2024-12-31

Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc. logo
Market Cap: Highest
Employees: Highest

EYLEA, Dupixent, Libtayo, Praluent, REGEN-COV, Kevzara, Inmazeb

Regeneron Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes medicines for treating various diseases worldwide, including treatments like EYLEA, Dupixent, Libtayo, and more.

Tags: biotechnology, diseases, healthcare, injections, medicines, pharmaceuticals, treatment

Symbol: REGN

Recent Price: $702.59

Industry: Biotechnology

CEO: Dr. Leonard S. Schleifer M.D., Ph.D.

Sector: Healthcare

Employees: 14165

Address: 777 Old Saw Mill River Road, Tarrytown, NY 10591-6707

Phone: 914 847 7000

Leadership

  • Leonard S. Schleifer, MD, PhD, Board co-Chair, President and Chief Executive Officer
  • George D. Yancopoulos, MD, PhD, Board co-Chair, President and Chief Scientific Officer
  • Zoran Berkovic, Senior Vice President, Financial Planning and Analysis
  • Maya Bermingham, Senior Vice President, Public Policy and Government Affairs
  • Leonard Brooks, Senior Vice President, Treasurer
  • John Calabro, Senior Vice President, Internal Audit
  • Christina Chan, Senior Vice President, Corporate Affairs
  • Larry Coury, PhD, Senior Vice President, Associate General Counsel
  • Ryan Crowe, Senior Vice President, Investor Relations & Strategic Analysis
  • Matthew Everett, Senior Vice President, Global Procurement
  • Chris Fenimore, Senior Vice President, Finance and Chief Financial Officer
  • Rick Hall, Senior Vice President, Human Resources
  • Justin Holko, Senior Vice President, Global Oncology/Hematology Commercial Business Unit
  • Nouhad Husseini, Senior Vice President, Business Development
  • Joseph J. LaRosa, Executive Vice President, General Counsel and Secretary
  • Melissa Lozner, Senior Vice President, Chief Compliance Officer
  • Marion McCourt, Executive Vice President, Commercial
  • Bob McCowan, Senior Vice President, IT and Chief Information Officer
  • Gonzalo Merino, PhD, Senior Vice President, Chief Intellectual Property Counsel and Associate General Counsel
  • Richard O’Neal, Senior Vice President, Market Access
  • Sally A. Paull, Executive Vice President, Human Resources
  • Smita Pillai, Senior Vice President, Culture and DEI and Chief DEI Officer
  • George Poth, Senior Vice President, Real Estate & Facilities Management
  • Alessandra Ravetti, Senior Vice President, Associate General Counsel
  • Kerry Reinertsen, PhD, Senior Vice President, Strategic Alliances
  • David Snow, Senior Vice President, Global Head, Dupixent Franchise
  • Mark Volpe, Senior Vice President, Tax
  • Bola Akinlade, MD, FACP, Senior Vice President, Clinical Development, Immunology and Inflammation
  • Hanne Bak, PhD, Senior Vice President, Preclinical Manufacturing and Process Development
  • Aris Baras, MD, Senior Vice President, Regeneron Genetics Center®
  • Ned Braunstein, MD, Executive Vice President, Regulatory Affairs and Global Patient Safety
  • Gang Chen, PhD, Senior Vice President, Protein Expression Sciences
  • Thomas DiCioccio, PhD, Senior Vice President, Pharmacometrics
  • Benjamin Drosman, Senior Vice President, Global Development Quality & Regulatory Compliance
  • Gregory Geba, MD, PhD, Senior Vice President, Global Development Scientific Council
  • Philip Gregory, DPhil, Senior Vice President, Regeneron Cell Medicines
  • Gary Herman, MD, Senior Vice President, Early Clinical Development and Experimental Sciences
  • Boaz Hirshberg, MD, Senior Vice President, Clinical Sciences General Medicine
  • Diana Hughes, MBBS, Senior Vice President, Global Patient Safety
  • Bari Kowal, Senior Vice President, Development Operations and Portfolio Management
  • Christos Kyratsous, PhD, Senior Vice President, Research
  • Johnathan Lancaster, MD, PhD, Senior Vice President, Global Medical Affairs
  • John Lin, MD, PhD, Senior Vice President, Immuno-Oncology and Head of Bispecifics
  • Israel Lowy, MD, PhD, Senior Vice President, Translational and Clinical Sciences, Oncology
  • Lynn Macdonald, PhD, Senior Vice President, Research
  • Lori Morton, PhD, Senior Vice President, Research
  • Andrew Murphy, PhD, Executive Vice President, Research
  • Muriel O'Byrne, PhD, Senior Vice President, International Regulatory Affairs & Head, European Business Office
  • William Olson, PhD, Senior Vice President, Therapeutic Proteins
  • Mohammed Shameem, PhD, Senior Vice President, Formulations Development
  • L. Andres Sirulnik, MD, PhD, Senior Vice President, Translational and Clinical Sciences, Hematology
  • Randy Soltys, PhD, Senior Vice President, Drug Safety and Pharmacometrics
  • Neil Stahl, PhD, Executive Vice President, Research and Development
  • Robert Vitti, MD, Senior Vice President, Clinical Trial Excellence Strategy
  • Brian Zambrowicz, PhD, Executive Vice President, Functional Genomics and Chief VelociGene® Operations
  • Rajesh Ahuja, Senior Vice President, Fill/Finish and External Manufacturing
  • Frederick Austin, Senior Vice President, Quality Control, Raheen
  • Christine Childrose, Senior Vice President, Human Resources and HR Operations
  • David Crenshaw, Senior Vice President, Associate General Counsel
  • Tikiri Dissanayake, Senior Vice President, IOPS Technical Operations
  • Patrice Gilooly, Senior Vice President, Quality Assurance and Operations
  • Jennifer McNay, PhD, Senior Vice President, CMC Regulatory Sciences and Industrial Affairs
  • Niall O’Leary, Senior Vice President and Site Head, IOPS Raheen
  • Scott Oberman, Senior Vice President, Supply Chain Operations
  • David Simon, Senior Vice President, IOPS Finance and Business Operations
  • Daniel Van Plew, Executive Vice President and General Manager, Industrial Operations and Product Supply
  • Benjamin Yocum, Senior Vice President, Manufacturing Operations
  • James Wolfe, Senior Vice President, Process Sciences and Drug Product Engineering
  • Bonnie L. Bassler, PhD, Director
  • Michael S. Brown, MD, Director
  • N. Anthony Coles, MD, Chair of the Board
  • Joseph L. Goldstein, MD, Director
  • Kathryn Guarini, PhD, Director
  • Christine A. Poon, Lead Independent Director
  • Arthur F. Ryan, Director
  • Huda Y. Zoghbi, MD, Director
  • Samantha Dickon, Director, Development Program Management
  • Gervasio Batista, Sr. Scientist, Neuroscience
  • James K. Gibson, Senior Regional Director, Immunology/Pulmonary
  • Beth Brause, Director, Field Reimbursement Management
  • Eric Prendergast, Director, Pricing Strategy
  • Ashley Neff, Manager, Digital Communications
  • Shari Loock, Associate Director, Sourcing
  • Jennifer Davidson Hamilton, VP and Head of Precision Medicine
  • Yi Zhang, Director, Health Economics & Outcomes Research
  • Wilson Caldwell III, Director, GCO Vendor & Relationship Management
  • David Stein, Director, Medical Operations
  • Regeneron, Corporate
  • Grant Anicete, Biotech Production Specialist I / IOPS Rensselaer
  • Mary McKenna, Lead Quality Control Analyst / IOPS Raheen
  • Ashley Lebby, Lead Senior Biotech Production Specialist / IOPS Rensselaer
  • Varenka Rodriguez Diblasi, Principal Scientist, Bioinformatics
  • Jessie Brown, Manager, Integrative Translational Genetics
  • Gisu Eom, Lead Cloud DevOps Engineer
  • Carmen Kenworthy, Scientist, Velocigene
  • Ralph Hazlewood, Sr. Manager, Research Program Management
  • Brandy Bennett, Sr. Director, R&D Strategy & Operations

Last updated: 2024-12-31

Kenvue Inc.

Kenvue Inc. logo
Market Cap: Highest
Employees: Highest

Tylenol, Nicorette, Zyrtec, Neutrogena, Aveeno, OGX, Listerine, Johnson's, Band-Aid, Stayfree

Kenvue Inc. operates as a consumer health company worldwide, focusing on self-care, skin health and beauty, and essential health products under various iconic brands.

Tags: Beauty, Consumer Health, Essential Health, Global Reach, Innovation, Self Care, Skin Health

Symbol: KVUE

Recent Price: $21.18

Industry: Household & Personal Products

CEO: Mr. Thibaut Mongon

Sector: Consumer Defensive

Employees: 22000

Address: 199 Grandview Road, Skillman, NJ 08558

Phone: (732) 524-0400

Leadership

  • Kathleen M. Pawlus, Independent Director
  • Kirk L. Perry, Independent Director

Last updated: 2024-12-31

Travere Therapeutics, Inc.

Travere Therapeutics, Inc. logo
Market Cap: Medium
Employees: Medium

Chenodal, Cholbam, Thiola, Sparsentan, TVT-058

Travere Therapeutics, Inc. is a biopharmaceutical company that focuses on identifying, developing, commercializing, and delivering therapies for the treatment of rare diseases. Its products include Chenodal, Cholbam, Thiola, and candidates like Sparsentan and TVT-058.

Tags: Chenodal, Cholbam, Sparsentan, TVT-058, Thiola, biopharmaceutical, rare diseases, therapeutics

Symbol: TVTX

Recent Price: $17.32

Industry: Biotechnology

CEO: Dr. Eric M. Dube Ph.D.

Sector: Healthcare

Employees: 380

Address: 3611 Valley Centre Drive, San Diego, CA 92130

Phone: 888 969 7879

Leadership

  • Eric Dube, Ph.D., President & Chief Executive Officer
  • Chris Cline, CFA, Chief Financial Officer
  • Angela Giannantonio, Senior Vice President, Human Resources
  • Peter Heerma, Chief Commercial Officer
  • Jula Inrig, M.D., Chief Medical Officer
  • Casey Logan, Chief Business Officer
  • Elizabeth Reed, J.D., Senior Vice President, General Counsel, Corporate Secretary
  • William Rote, Ph.D., Senior Vice President, Research & Development
  • Charlotte Smith, Senior Vice President, Public Affairs
  • Gary A. Lyons, Chairman
  • Roy D. Baynes, M.D., Ph.D.,
  • Suzanne L. Bruhn, Ph.D.,
  • Tim Coughlin, CPA,
  • Jeffrey A. Meckler,
  • John A. Orwin,
  • Sandra E. Poole,
  • Ron Squarer,
  • Ruth Williams-Brinkley, FACHE,

Last updated: 2024-12-31

Ardelyx, Inc.

Ardelyx, Inc. logo
Market Cap: High
Employees: Low

tenapanor

Ardelyx, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing medicines for gastrointestinal and cardiorenal therapeutic areas, including treatments for irritable bowel syndrome with constipation and hyperphosphatemia.

Tags: CKD, biopharmaceutical, cardiorenal, gastrointestinal, hyperkalemia, hyperphosphatemia, metabolic acidosis, tenapanor

Symbol: ARDX

Recent Price: $5.25

Industry: Biotechnology

CEO: Mr. Michael G. Raab

Sector: Healthcare

Employees: 267

Address: 400 Fifth Avenue, Waltham, MA 02451

Phone: 510 745 1700

Leadership

  • Justin Renz, Chief Financial & Operations Officer
  • Eric Foster, Chief Commercial Officer
  • Elizabeth Grammer, Esq., Chief Legal & Administrative Officer
  • Laura Williams, MD MPH, Chief Medical Officer
  • Robert Blanks, MS RAC, Chief Regulatory Affairs & Quality Assurance Officer
  • David Rosenbaum, PhD, Chief Development Officer
  • Mike Kelliher, Executive Vice President, Corporate Development and Strategy
  • Charon Spencer, Chief Human Resources Officer
  • David Mott, Chairman
  • Robert Bazemore, Director
  • William A. Bertrand, Jr., JD, Director
  • Muna Bhanji, R.Ph, Director
  • Onaiza Cadoret-Manier, Director
  • Mike Raab, Director
  • Richard Rodgers, Director

Last updated: 2024-12-31

BioCryst Pharmaceuticals, Inc.

BioCryst Pharmaceuticals, Inc. logo
Market Cap: High
Employees: Medium

ORLADEYO

Bio Cryst Pharmaceuticals, Inc. is a biotechnology company focused on discovering novel, oral, and small-molecule medicines, with marketed products including RAPIVAB and ORLADEYO, and a pipeline featuring BCX9930, BCX9250, and Galidesivir.

Tags: biotechnology, clinical trials, hereditary angioedema, influenza treatment, oral medicines, small-molecule medicines

Symbol: BCRX

Recent Price: $7.53

Industry: Biotechnology

CEO: Mr. Jon P. Stonehouse

Sector: Healthcare

Employees: 536

Address: 4505 Emperor Boulevard, Durham, NC 27703

Phone: 919 859 1302

Last updated: 2024-12-31

BeiGene, Ltd.

BeiGene, Ltd. logo
Market Cap: Highest
Employees: Highest

BRUKINSA, Tislelizumab, REVLIMID, VIDAZA, XGEVA, BLINCYTO, KYPROLIS, SYLVANT, QARZIBA, Pamiparib, Pobevcy

Bei Gene, Ltd. is a biotechnology company focused on discovering, developing, manufacturing, and commercializing a wide range of medicines globally, specializing in oncology treatments and clinical stage drug candidates.

Tags: Biotechnology, Medicines, Oncology, Pharmaceuticals, Research and Development

Symbol: BGNE

Recent Price: $183.81

Industry: Biotechnology

CEO: Mr. John V. Oyler

Sector: Healthcare

Employees: 10000

Address: 55 Cambridge Parkway, Cambridge, MA 02142

Phone: 781-801-1800

Leadership

  • John V. Oyler, Co-Founder, Chairman and CEO
  • Xiaodong Wang, Ph.D., Co-Founder, Chairman of Scientific Advisory Board
  • Olivier Brandicourt, M.D., Director
  • Margaret Dugan, M.D., Director
  • Donald W. Glazer, Director
  • Michael Goller, Director
  • Anthony Hooper, Director
  • Ranjeev Krishana, Director
  • Michael Nuoqing Yi, Director
  • Alessandro Riva, M.D., Director
  • Corsee Sanders, Ph.D., Director
  • Shalini Sharp, Director
  • Steven Young, Ph.D., Acting Head of Medicinal Chemistry
  • Ron Levy, M.D., Scientific Advisory Board
  • Neal Rosen, M.D., Ph.D., Scientific Advisory Board
  • Charles Sawyers, M.D., Scientific Advisory Board
  • David Schenkein, M.D., Scientific Advisory Board
  • Melika Davis, SVP & Global Head, Clinical Operations
  • Clare Fisher, SVP, Business Development, Licensing, and M&A (ex-China)
  • Tony Guo, Ph.D., SVP, Global Statistics & Data Science
  • Dany Habr, M.D., Head of Medical Affairs, North America & International Markets
  • Graham Hardiman, Global Head of HR
  • Shreya Devendra Jani, SVP, Corporate Affairs
  • Jaspreet Jaggi, M.D., Ph.D., SVP and Head, Clinical Portfolio Strategy
  • Yang Ji, Chief Compliance Officer
  • Mark Lanasa, M.D., Ph.D., SVP, Chief Medical Officer, Solid Tumors
  • Chan Lee, General Counsel
  • Kyu-Sung Lee, Ph.D., SVP, Global Head of Technical Operations and Manufacturing
  • Julie Lepin, Senior Vice President and Chief Regulatory Affairs Officer
  • Kyoung Lim, VP of Supply Chain
  • Han Ma, M.D., Ph.D., Chief Safety Officer and SVP, Global Patient Safety
  • Mehrdad Mobasher, M.D., M.P.H., Chief Medical Officer, Hematology
  • Richard O’Keeffe, Head of Global Quality
  • Jurij Petrin, M.D., Head of New Market Development
  • Yan Qi, Ph.D., SVP, Head of Public Affairs
  • Hongyu Qian, SVP, Medical Affairs
  • Jason Radford, SVP, Strategy & Corporate Development
  • Anand Reddi, VP, Global Strategic Initiatives and Corporate Operations, Chief of Staff to the CEO
  • Adam Roach, VP and Head of Asia Pacific
  • Aaron Rosenberg, Chief Financial Officer
  • Michael Schoen, Strategic Advisor and Special Assistant to the CEO
  • Matt Shaulis, General Manager of North America
  • Lai Wang, Ph.D., Global Head of R&D
  • Zhiwei Wang, Ph.D., SVP, Research Head of Chemistry
  • Beth Wensley, SVP, Head of Portfolio and Program Management
  • Kimberly Wolf, SVP, Global Commercial Strategy & Operations
  • Xiaobin Wu, Ph.D., President, Chief Operating Officer
  • Eva Yin, Chief Commercial Officer, Greater China

Last updated: 2024-12-31

Inovio Pharmaceuticals, Inc.

Inovio Pharmaceuticals, Inc. logo
Market Cap: Low
Employees: Low

DNA Medicines

Inovio Pharmaceuticals is a biotechnology company focused on discovering, developing, and commercializing DNA medicines to treat and protect against diseases like HPV, cancer, and infectious diseases. Their platform includes Syn Con designed DNA sequences and CELLECTRA smart devices technology for delivery.

Tags: DNA medicines, HPV, biotechnology, cancer, clinical studies, infectious diseases

Symbol: INO

Recent Price: $1.78

Industry: Biotechnology

CEO: Dr. Jacqueline E. Shea Ph.D.

Sector: Healthcare

Employees: 127

Address: 660 West Germantown Pike, Plymouth Meeting, PA 19462

Phone: 267 440 4200

Leadership

  • Jacqueline Shea, Ph.D., President & Chief Executive Officer
  • Peter Kies, Chief Financial Officer
  • Michael Sumner, MB BS, MBA, Chief Medical Officer
  • Laurent Humeau, Ph.D., Chief Scientific Officer; Chairman, Scientific Advisory Board
  • Steve Egge, MBA, Chief Commercial Officer
  • Rob Crotty, J.D., General Counsel and Chief Compliance Officer
  • EJ Brandreth, MBA, Senior Vice President, Quality Assurance
  • Shawn Bridy, MA, MBA, Senior Vice President, Business Development
  • Cheryl Elder, PharmD, Senior Vice President, Regulatory Affairs
  • Robert J. Juba Jr., Senior Vice President, Biological Manufacturing and Clinical Supply Management
  • Jeffrey Skolnik, M.D., Senior Vice President, Clinical Development
  • Dave Liebowitz, M.D. & Ph.D., Senior Vice President, Early-Stage Clinical Development
  • Simon X. Benito, Chairman of the Board, Inovio Pharmaceuticals
  • Roger D. Dansey, M.D., Chief Medical Officer at Seagen
  • Ann C. Miller, M.D., Former Head of Sanofi Oncology Global Marketing
  • Jay Shepard, Former President & CEO of Aravive
  • David B. Weiner, Ph.D., Executive Vice President, Director, Vaccine Center, The Wistar Institute
  • Wendy L. Yarno, MBA, Former Executive Vice President and Chief Marketing Officer at Merck & Co., Inc.
  • Lota S. Zoth, CPA, Former Chief Financial Officer, MedImmune
  • Rafi Ahmed, Ph.D., Director, Emory Vaccine Center, Emory University School of Medicine
  • Stanley A. Plotkin, M.D., Emeritus Professor, Wistar Institute and University of Pennsylvania; Principal, Vaxconsult

Last updated: 2024-12-31

Innoviva, Inc.

Innoviva, Inc. logo
Market Cap: Medium
Employees: Low

RELVAR/BREO ELLIPTA, ANORO ELLIPTA, TRELEGY ELLIPTA

Innoviva, Inc. engages in the development and commercialization of pharmaceuticals, focusing on respiratory therapies with its product line including RELVAR/BREO ELLIPTA, ANORO ELLIPTA, and TRELEGY ELLIPTA. The company collaborates with Sarissa Capital Management and Glaxo Group Limited.

Tags: COPD, asthma, partnerships, pharmaceuticals, respiratory therapies

Symbol: INVA

Recent Price: $17.38

Industry: Biotechnology

CEO: Mr. Pavel Raifeld C.F.A.

Sector: Healthcare

Employees: 112

Address: 1350 Old Bayshore Highway, Burlingame, CA 94010

Phone: 650 238 9600

Last updated: 2024-12-31

Kala Pharmaceuticals, Inc.

Kala Pharmaceuticals, Inc. logo
Market Cap: Lowest
Employees: Lowest

KPI-012, EYSUVIS, INVELTYS

Kala Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing therapies for eye diseases using proprietary mucus penetrating particles technology.

Tags: biopharmaceutical, corneal epithelial defects, dry eye disease, eye diseases, gene expression, mucus penetrating particles, ocular surgery, retinal diseases

Symbol: KALA

Recent Price: $6.87

Industry: Drug Manufacturers - Specialty & Generic

CEO: Mr. Mark T. Iwicki

Sector: Healthcare

Employees: 43

Address: 1167 Massachusetts Avenue, Arlington, MA 02476

Phone: 781 996 5252

Last updated: 2024-12-31

Ligand Pharmaceuticals Incorporated

Ligand Pharmaceuticals Incorporated logo
Market Cap: High
Employees: Lowest

Kyprolis, Evomela, Veklury, Teriparatide, Vaxneuvance, Pneumosil, Rylaze, Nexterone, Zulresso, Noxafil-IV

Ligand Pharmaceuticals Incorporated is a biopharmaceutical company focused on developing or acquiring technologies to aid pharmaceutical companies in discovering and developing medicines. The company's commercial programs include treatments for multiple myeloma, COVID-19, osteoporosis, invasive diseases, childhood pneumonia, and acute lymphoblastic leukemia.

Tags: biopharmaceutical, commercial programs, disease treatment, medicine development, pharmaceutical technology

Symbol: LGND

Recent Price: $105.76

Industry: Biotechnology

CEO: Mr. Todd C. Davis Ph.D.

Sector: Healthcare

Employees: 58

Address: 5980 Horton Street, EmeryVille, CA 94608

Phone: 858 550 7500

Last updated: 2024-12-31

Ocuphire Pharma, Inc.

Ocuphire Pharma, Inc. logo
Market Cap: Lowest
Employees: Lowest

Nyxol

Ocuphire Pharma, Inc. is a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders.

Tags: biopharmaceutical, clinical trials, ophthalmic, refractive disorders, retinal disorders

Symbol: OCUP

Recent Price: $1.17

Industry: Biotechnology

CEO: Mr. George Magrath M.B.A., M.D., M.S.

Sector: Healthcare

Employees: 14

Address: 37000 Grand River Avenue, Farmington Hills, MI 48335

Phone: 248 681 9815

Last updated: 2024-12-31

Ovid Therapeutics Inc.

Ovid Therapeutics Inc. logo
Market Cap: Low
Employees: Lowest

OV101, OV329, OV350, OV882, OV815

Ovid Therapeutics Inc., a biopharmaceutical company based in New York, is dedicated to developing impactful medicines for neurological disorders. They have a range of drug candidates like OV101 and are involved in various clinical trials.

Tags: biopharmaceutical, clinical trials, medicine development, neurological disorders

Symbol: OVID

Recent Price: $0.96

Industry: Biotechnology

CEO: Dr. Jeremy Max Levin Ba Zoology, Dphil, M.D., Mb Bchir, Ph.D.

Sector: Healthcare

Employees: 40

Address: 1460 Broadway, New York, NY 10036

Phone: 646 661 7661

Leadership

  • Jeremy M. Levin, D.Phil, MB BChir, Chief Executive Officer and Chairman
  • Meg Alexander, President and Chief Operating Officer
  • Zhong Zhong, Ph.D., Chief Scientific Officer
  • Jeffrey Rona, Chief Business and Financial Officer
  • Amanda Banks, M.D., Chief Development Officer
  • Julia Tsai, Ph.D., Senior Vice President of Clinical Development
  • Karen Bernstein, Ph.D., Director, Chair of the Compensation Committee, Member of the Audit and Nominating and Corporate Governance Committees
  • Barbara G. Duncan, MBA, Director, Chair of the Audit Committee, Member of the Nominating and Corporate Governance Committee
  • Bart Friedman, J.D., Lead Independent Director, Chair of the Nominating and Corporate Governance Committee, Member of the Audit and Compensation Committees
  • Michael Poole, M.D., FACP, Director, Member of the Audit and Compensation Committees
  • Kevin Fitzgerald, Ph.D., Director, Member of the Nominating and Corporate Governance Committee

Last updated: 2024-12-31

Trevena, Inc.

Trevena, Inc. logo
Market Cap: Lowest
Employees: Lowest

OLINVYK (Oliceridine) injection

Trevena, Inc. is a biopharmaceutical company focused on developing and commercializing novel medicines for central nervous system disorders, with products like OLINVYK and collaborations such as with Imperial College London.

Tags: COVID-19, acute pain, biopharmaceutical, central nervous system disorders, chronic pain, migraine

Symbol: TRVN

Recent Price: $1.50

Industry: Biotechnology

CEO: Ms. Carrie L. Bourdow

Sector: Healthcare

Employees: 23

Address: 955 Chesterbrook Boulevard, Chesterbrook, PA 19087

Phone: 610 354 8840

Leadership

  • Carrie L. Bourdow, President and Chief Executive Officer
  • Mark A. Demitrack, MD, Senior Vice President, Chief Medical Officer
  • Barry Shin, Executive Vice President, Chief Operating Officer and Chief Financial Officer
  • Robert T. Yoder, Senior Vice President, Chief Business Officer, Head of Commercial Operations & Chief Compliance Officer
  • Scott Braunstein, M.D., Lead Independent Director
  • Dr. Mark Corrigan, Acting CEO
  • Marvin H. Johnson, Jr., Board Member
  • Jake R. Nunn, Board Member
  • Anne M. Phillips, M.D., Board Member
  • Barbara Yanni, Board Member

Last updated: 2024-12-31

Theriva Biologics, Inc.

Theriva Biologics, Inc. logo
Market Cap: Lowest
Employees: Lowest

SYN-004, SYN-020, VCN-01

Theriva Biologics Inc. is a clinical-stage company developing therapeutics to address diseases with high unmet needs, including SYN-004 for preventing microbiome damage and SYN-020 for treating GI and systemic diseases.

Tags: biologics, biopharmaceutical, clinical-stage, disease treatment, microbiome, therapeutics

Symbol: TOVX

Recent Price: $1.50

Industry: Biotechnology

CEO: Mr. Steven A. Shallcross CPA

Sector: Healthcare

Employees: 22

Address: 9605 Medical Center Drive, Rockville, MD 20850

Phone: 301 417 4364

Last updated: 2024-12-31

Avenue Therapeutics, Inc.

Avenue Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Lowest

intravenous Tramadol

Avenue Therapeutics, Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the acute/intensive care hospital setting. The company is advancing intravenous Tramadol, a synthetic dual-acting opioid, in Phase III clinical trials for post-operative acute pain treatment.

Tags: acute care, clinical trials, intensive care, intravenous Tramadol, opioids, pain management, pharmaceutical

Symbol: ATXI

Recent Price: $1.94

Industry: Biotechnology

CEO: Dr. Alexandra MacLean M.D.

Sector: Healthcare

Employees: 3

Address: 1140 Avenue of the America, New York, NY 10036

Phone: 781 652 4500

Leadership

  • Jay Kranzler, MD, PhD, Chairman of the Board of Directors
  • Alexandra MacLean, MD, Director
  • David Jin, Interim Chief Financial Officer
  • Scott A. Reines, MD, PhD, Interim Chief Medical Officer
  • Michael Ryan, MS, Vice President of Clinical Operations and Program Management
  • Alix MacLean, Chief Executive Officer
  • Lindsay A. Rosenwald, MD, Director
  • Neil Herskowitz, Director
  • Curtis Oltmans, Director
  • Faith Charles, Director

Last updated: 2024-12-31

Indivior PLC

Indivior PLC logo
Market Cap: High
Employees: Medium

SUBLOCADE, SUBUTEX PRO, SUBOXONE, SUBUTEX, OPVEE, PERSERIS

Indivior PLC is focused on the development, manufacture, and sale of buprenorphine-based prescription drugs for opioid dependence and co-occurring disorders. The company's products treat substance use disorders, serious mental illnesses, and opioid overdose prevention, and they include SUBLOCADE, SUBUTEX PRO, SUBOXONE, SUBUTEX, OPVEE, and PERSERIS. Indivior is also advancing INDV-2000, a new treatment in the clinical trial phase.

Tags: Addiction Medicine, Clinical Trials, Mental Health, Opioid Treatment, Pharmaceuticals, Substance Use Disorders

Symbol: INDV

Recent Price: $12.18

Industry: Drug Manufacturers - Specialty & Generic

CEO: Mr. Mark Crossley

Sector: Healthcare

Employees: 1000

Address: 10710 Midlothian Turnpike, North Chesterfield, VA 23235

Phone: 804 379 1090

Last updated: 2024-12-31